In conclusion, our high-throughput drug combination screening unveiled that targeting the critical therapeutic target-LSD1, is sufficient to enhance the therapeutic efficacy of Lenvatinib in liver cancer cell lines via disrupting the PI3K-AKT signaling transduction and therefore triggering the apoptotic events. The gene discussed is AKT1; the disease is liver cancer.